一品红：子公司获得左卡尼汀口服溶液注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of L-Carnitine oral solution, which is indicated for treating primary systemic carnitine deficiency and related conditions [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for L-Carnitine oral solution [1] - The approved indication for L-Carnitine oral solution includes treatment for primary systemic carnitine deficiency, which can manifest as recurrent Reye-like syndrome, hypoketotic hypoglycemia, and/or cardiomyopathy [1] - The product is also indicated for short-term and long-term treatment of secondary carnitine deficiency due to congenital metabolic disorders, with recommended dosages for infants and children included in the instructions [1] Group 2: Product Functionality - L-Carnitine is a naturally occurring substance essential for energy metabolism in mammals, primarily facilitating lipid metabolism [1] - The main functions of L-Carnitine include transporting long-chain fatty acids into the mitochondrial matrix for oxidation and providing energy to cells, as well as exporting short-chain acyl groups produced within the mitochondria [1] - Supplementation of L-Carnitine can alleviate metabolic disorders caused by its deficiency, improving the functionality of skeletal muscle and cardiac tissues [1]